Key result
Total plasma adiponectin was identified as an independent predictor of the occurrence of left ventricular hypertrophy in subjects with metabolic syndrome.
Why the study?
Does total plasma adiponectin predict the occurrence of left ventricular hypertrophy in subjects with metabolic syndrome?
Observational
Does total plasma adiponectin predict the occurrence of left ventricular hypertrophy in subjects with metabolic syndrome?
Circulating adiponectin is an independent predictor of left ventricular hypertrophy in patients with metabolic syndrome, suggesting it acts as a nonhaemodynamic factor in LVH development.
Adiponectin may aid LVH risk stratification in metabolic syndrome; leaves open causality and need for prospective validation.
This study was designed to evaluate the role of total plasma adiponectin (ADPN) on the occurrence of left ventricular hypertrophy in subjects with metabolic syndrome (MetS) compared to a control group without MetS. The main finding of our study concerns the independent predictor role of ADPN in the occurrence of LVH in all the patients studied. Accordingly, circulating ADPN might be considered a nonhaemodynamic factor of LVH in subjects with MetS.
No takes yet. Share an insight, caveat, or question.
Scaglione et al. (2017) conducted an observational in Metabolic syndrome. Total plasma adiponectin (ADPN) vs. Control group without metabolic syndrome was evaluated on Occurrence of left ventricular hypertrophy (LVH). Total plasma adiponectin was identified as an independent predictor of the occurrence of left ventricular hypertrophy in subjects with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: